Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with ...
TARPON SPRINGS, Fla., April 27, 2026 - Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...
Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results